Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 2/20 | 0.52 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | AR | P10275 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11982737 | 0.90 | MAPT (0.54) | CYP1A1CYP1B1MAPTGAARECQL | |
| SCHEMBL11982626 | 0.86 | MAPT (0.51) | MAPTGAARECQLGFER | |
| SCHEMBL11982658 | 0.85 | KDM1A (0.50) | CYP1A1CYP1B1MAPTGAARECQL | |
| SCHEMBL13764343 | 0.85 | GRM5 (0.47) | MAPTGAARECQLARNPC1 | |
| SCHEMBL11982729 | 0.85 | GRM5 (0.47) | MAPTGAARECQLARNPC1 | |
| SCHEMBL13764341 | 0.82 | GRM5 (0.47) | MAPTGAARECQLARNPC1 | |
| SCHEMBL11982617 | 0.81 | MAPT (0.55) | MAPTGAARECQLGFERNPC1 | |
| SCHEMBL13764344 | 0.81 | MAPT (0.43) | MAPTGAARECQLGFERAR | |
| SCHEMBL8241108 | 0.81 | GRM5 (0.65) | GRM5 | |
| SCHEMBL8239076 | 0.80 | GRM5 (0.63) | MAPTGAARECQLARNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203903-A1 | Thiazolyl mglur5 antagonists and methods for their use | MERCK SHARP & DOHME LLC | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203903-A1 | Thiazolyl mglur5 antagonists and methods for their use | GRM5, GRIK5, GRM3 | CYP1A1 3513/4885CYP1B1 3849/4885MAPT 1999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.